

( (S (NP-SBJ-1 (NP The University)
	       (PP of
		   (NP Toronto)))
     (VP stepped
         (ADVP deeper)
	 (PP-DIR into
		 (NP (NP the contest)
		     (PP for
			 (NP Connaught BioSciences Inc.))))
	 (PP-MNR by
		 (S-NOM (NP-SBJ *-1)
			(VP reaching
			    (NP an unusual agreement)
			    (PP-CLR with
				    (NP (NP Ciba-Geigy Ltd.)
					and
					(NP Chiron Corp)))))))
     .))
( (S (NP-SBJ The University)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 the two companies)
		  (VP agreed
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP spend
				 (NP (NP (QP 25 million) Canadian dollars)
				     -LRB-
				     (NP (QP $ 21.3 million) *U*)
				     -RRB-)
				 (PP-TMP over
					 (NP 10 years))
				 (PP-CLR on
					 (NP (NP research)
					     (PP-LOC at
						     (NP Canadian universities)))))))
		      (SBAR-ADV if
				(S (NP-SBJ-2 they)
				   (VP are
				       (ADJP-PRD successful)
				       (PP-LOC in
					       (S-NOM (NP-SBJ *-2)
						      (VP acquiring
							  (NP the vaccine maker)))))))))))
     .))
( (S (NP-SBJ It)
     (VP said
         (SBAR 0
               (S (NP-SBJ (QP $ 10 million) *U*)
                  (VP would
                      (VP go
                          (PP-DIR to
				  (NP (NP the University)
				      (PP of
					  (NP Toronto)))))))))
     .))
( (S (S (NP-SBJ (NP Ciba-Geigy)
                and
                (NP Chiron))
        (VP have
            (VP made
                (NP (NP a joint bid)
                    (PP of
                        (NP (QP C$ 866 million) *U*))
                    (PP for
                        (NP Connaught))))))
     , and
     (S (NP-SBJ (NP Institut Merieux S.A.)
                (PP of
                    (NP France)))
        (VP has
            (VP made
                (NP (NP a rival bid)
                    (PP of
                        (NP (QP C$ 942 million) *U*))))))
     .))
( (S (NP-SBJ-2 The University)
     (VP is
         (VP seeking
             (NP (NP an injunction)
		 (PP against
		     (NP the Merieux bid)))
	     ,
	     (S-ADV (NP-SBJ *-2)
		    (VP arguing
			(SBAR that
			      (S (NP-SBJ (NP Connaught 's)
					 predecessor company)
				 (VP agreed
				     (PP-TMP in
					     (NP 1972))
				     (SBAR that
					   (S (NP-SBJ-1 (NP Connaught 's)
							ownership)
					      (VP would n't
						  (VP be
						      (VP transferred
							  (NP *-1)
							  (PP-DTV to 
								  (NP foreigners))))))))))))))
     .))
( (S (NP-SBJ The university)
     (VP implied
         (SBAR that
               (S (NP-SBJ it)
		  (VP would
		      (VP drop
			  (NP (NP its opposition)
			      (PP to
				  (NP foreign ownership)))
			  (SBAR-ADV if
				    (S (NP-SBJ (NP Ciba-Geigy)
					       and
					       (NP Chiron))
				       (VP are
					   (ADJP-PRD successful
						     (PP with
							 (NP their lower bid)))))))))))
     .))
( (S (NP-SBJ It)
     (VP said
         (SBAR 0
               (S (NP-SBJ the new agreement)
                  (VP would
                      (VP `` replace ''
                          (NP (NP the old one)
                              (SBAR (WHNP-1 that)
                                    (S (NP-SBJ *T*-1)
                                       (VP forms
                                           (NP (NP the basis)
                                               (PP of
                                                   (NP (NP its suit)
                                                       (PP against
                                                           (NP the Merieux takeover))))))))))))))
     .))
( (SINV ``
	(S-TPC-1 (PP Notwithstanding
		     (NP (NP foreign ownership)
			 (PP of
			     (NP Connaught))))
		 ,
		 (NP-SBJ this accord)
		 (VP would
		     (VP enhance
			 (NP (NP research and development)
			     (PP-LOC in
				     (NP Canada))))))
	, ''
	(VP said
	    (S *T*-1))
	(NP-SBJ (NP James Keffer)
		,
		(NP (NP (NP the university 's)
			vice president)
		    (PP of
			(NP research))))
	.))
( (S (S (NP-SBJ Ciba-Geigy)
        (VP is
            (NP-PRD a Swiss pharmaceutical company)))
     and
     (S (NP-SBJ-1 Chiron)
        (VP is
            (VP based
                (NP *-1)
                (PP-LOC-CLR in
			    (NP (NP Emeryville)
				,
				(NP Calif))))))
     .))
( (S (PP-LOC In
	     (NP a statement))
     ,
     (NP-SBJ (NP Jacques-Francois Martin)
             ,
             (NP (NP director general)
                 (PP of
                     (NP Merieux)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 the French company)
                  (VP is
                      (ADVP still)
		      (ADJP-PRD determined
				(S (NP-SBJ *-1)
				   (VP to
				       (VP acquire
					   (NP Connaught)))))))))
     .))
( (S (SBAR-ADV While
	       (S (NP-SBJ he)
		  (VP did n't
		      (VP comment
			  (ADVP-MNR directly)
			  (PP-CLR on
				  (NP (NP the pact)
				      (PP between
					  (NP (NP Ciba-Geigy)
					      and
					      (NP the university)))))))))
     ,
     (NP-SBJ he)
     (VP said
         (SBAR 0
               (S (NP-SBJ Merieux)
                  (VP can
                      (VP transfer
                          (NP new products and technologies)
                          (PP-CLR to 
				  (NP Connaught))
                          (ADVP-MNR (ADVP more rapidly)
				    (PP than
					(NP (NP other companies)
					    ``
					    (VP not
						(ADVP-TMP currently)
						producing and marketing
						(NP vaccines))
					    (SBAR -LCB-
						  (WHNP-2 who)
						  -RCB-
						  (S (NP-SBJ *T*-2)
						     (VP can
							 (ADVP only)
							 (VP promise
							     (NP this)
							     (PP-CLR for
								     (NP (NP some ... years)
									 (PP-TMP in
										 (NP the future))))))))))))))))
     .
     ''))
( (S (PP-LOC In
	     (NP national over-the-counter trading))
     (NP-TMP yesterday)
     ,
     (NP-SBJ Connaught)
     (VP closed
	 (PP-CLR at
		 (NP $ 28.625 *U*))
	 ,
	 (ADVP up
	       (NP $ 1.25 *U*)))
     .))
